Oxfordshire Clinical Commissioning Group
Formulary
 
back
8 Malignant disease and immunosuppression
08-01-05 Erlotinib

Erlotinib Tarceva®
Formulary

Red Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer as per NICE TA258 (APCO September 2012).


Black Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK NEGATIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • Monotherapy for maintenance treatment of non-small-cell lung cancer as per NICE TA227 (APCO September 2011).

Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 

View adult BNF  View SPC online  View childrens BNF  HCD